Can cholesterol drugs shield the heart during melanoma immunotherapy?
NCT ID NCT07704918
First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time
Summary
This study investigates whether aggressive lipid-lowering therapy can reduce plaque buildup in the heart arteries of melanoma patients starting immune checkpoint inhibitors (ICIs). Participants with plaque detected on a heart CT scan are randomly assigned to either usual care or aggressive treatment with statins and other cholesterol-lowering drugs, aiming for very low LDL levels. The trial tracks changes in LDL cholesterol and plaque volume over 12 months to see if this approach protects heart health during cancer treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Statins (atorvastatin, rosuvastatin, simvastatin, or pravastatin), +/- ezetimibe, +/- PCSK9 inhibitor (alirocumab, evolocumab, inclisiran)
- What this could lead to
- If successful, this could show that aggressive cholesterol-lowering therapy protects the heart arteries of melanoma patients treated with immune checkpoint inhibitors.
- What could go wrong
- This is a small, early-phase study with only 40 participants, so results may not apply broadly. The aggressive therapy may cause side effects like muscle pain or liver issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Colorado Hospital
Aurora, Colorado, 80045, United States
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer reveal whether immunotherapy is working?
- Can a new nucleotide analogue boost cancer treatment?
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- Can a single tracer light up cancer's first stop? a trial puts a hybrid dye-and-radioactive marker to the test.
- Botox before the knife: could a Pre-Surgery injection lead to Better-Looking scars?
- Could a lighter immunotherapy schedule keep advanced cancers in check?